ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis and Metrics

Sector: Healthcare Industry: Biotechnology CIK: 0001671858

Market Cap 770.30 Mn

P/E -4.47

P/S 9.14

Div. Yield 0.00

Revenue Growth (1y) (Qtr) -67.56

Add ratio to table...

About

ARS Pharmaceuticals, Inc., or ARS Pharma, is a biopharmaceutical company that operates within the healthcare industry. The company is focused on the development and commercialization of its novel product candidate, neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy, which was previously referred to as ARS-1, is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, allowing it to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry,...

ARS Pharmaceuticals, Inc., or ARS Pharma, is a biopharmaceutical company that operates within the healthcare industry. The company is focused on the development and commercialization of its novel product candidate, neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy, which was previously referred to as ARS-1, is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, allowing it to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered, and reliable nasal spray.

ARS Pharma's main business activities revolve around the development and commercialization of neffy. The company's operations are based in the United States, where it is headquartered, and it has partnerships for the development and commercialization of neffy in regions outside of the United States, including Japan and China.

The company generates revenue through the development and commercialization of neffy. As a proprietary composition of epinephrine with an innovative absorption enhancer, neffy has the potential to address the limitations of epinephrine intra-muscular injectable products, which are currently the standard treatment for Type I allergic reactions. Neffy's user-friendly delivery method, as a nasal spray, aims to provide a more convenient and reliable option for patients.

In terms of competition, ARS Pharma is well-positioned to commercialize neffy as a potentially first-in-class approved intranasal treatment for Type I allergic reactions, including anaphylaxis. The company has a robust global intellectual property portfolio, including issued composition of matter and method patents relating to neffy, which are not expected to expire until 2038. These patents provide ARS Pharma with a strong competitive advantage in the market.

ARS Pharma has entered into partnerships for the development and commercialization of neffy in regions outside of the United States, including Japan and China. These partnerships further strengthen the company's position in the market and allow it to reach a wider patient base.

ARS Pharma's regulatory submissions for neffy are currently under review by the FDA and the European Medicines Agency (EMA). The company expects to submit regulatory filings equivalent to an NDA in China and Japan by year-end 2024.

If neffy is approved by the FDA, ARS Pharma plans to commercialize it in the United States through a combination of direct promotion, virtual sales consultants, and non-personal promotion. The company will target high-prescribing allergists, pediatricians, and primary care physicians through both traditional and non-traditional professional channels. ARS Pharma will also commercialize neffy outside of the United States with its partners, including Alfresa Pharma in Japan and Pediatrix Therapeutics in China.

Investment thesis

Bull case

The third‑quarter surge in U.S. net product revenue, driven by a 2.5‑fold increase to $31.3 million, demonstrates that Nephi’s pricing and positioning are resonating with both prescribers and patients. New prescriber market share now sits at 10.3 percent, outpacing existing prescribers, which signals a shift in the industry where ease of use and needle‑free delivery are becoming the deciding factors. The company’s direct‑to‑consumer campaign has increased brand awareness from 20 percent to 56 percent, and 80 percent of surveyed patients now feel strongly enough to ask their doctors about Nephi, indicating a growing pipeline of potential prescriptions. Coupled with a 95 percent likelihood to refill among users versus only 30 percent for traditional injectors, the data suggest a durable utilization pattern that will help drive incremental sales and revenue.
Nephi’s penetration into new patient segments—19 percent lapsed users and 7 percent previously untreated—highlights its ability to expand the overall epinephrine market rather than simply taking share from existing competitors. This shift is supported by high patient satisfaction scores, with 87 percent reporting positive impacts on daily and social life, and the company’s ability to capture these segments speaks to unmet needs that injection products have historically failed to address. By addressing needle anxiety and simplifying the device, Nephi is positioned to convert a larger portion of the 2 billion‑dollar U.S. epinephrine market, creating upside as the market continues to grow organically at 6‑8 percent per year. The expansion into new segments also improves the company's gross‑to‑net retention profile, as cash prescriptions drop from 20 percent to 12 percent, reducing discounting pressures and improving profitability.
The global rollout strategy is accelerating, with YERNEPI already in Germany, the United Kingdom, Japan, Canada, and China slated for 2026, and each market presenting distinct but complementary access frameworks. Germany’s uptake has been three times faster than in the United States because of a seamless prescribing process that eliminates prior authorizations, underscoring how administrative friction can accelerate adoption. The UK launch has already generated strong enthusiasm among prescribers, and Japan’s approval in September with an expected 2025 launch will tap into a large and growing allergic disease patient base. Early traction in these markets suggests that Nephi can rapidly scale its commercial model outside the United States, diversifying revenue streams and mitigating U.S. market seasonality risks.
The Phase 2b urticaria program positions Nephi to tap into a $2 million patient U.S. market, with early market research indicating a 60 percent adoption potential among chronic spontaneous urticaria patients. Successful top‑line data in 2026 could add a high‑margin indication to the product portfolio, leveraging existing manufacturing and distribution capabilities while providing a new revenue stream that is less susceptible to seasonal demand swings. The trial is aligned with a patient segment that is already on antihistamines or biologics, suggesting that Nephi could serve as a bridging or rescue therapy, further expanding its utility and prescription frequency. The successful label expansion would also differentiate Nephi from competitors that focus solely on epinephrine, thereby enhancing the company’s competitive moat.

The third‑quarter surge in U.S. net product revenue, driven by a 2.5‑fold increase to $31.3 million, demonstrates that Nephi’s pricing and positioning are resonating with both prescribers and patients. New prescriber market share now sits at 10.3 percent, outpacing existing prescribers, which signals a shift in the industry where ease of use and needle‑free delivery are becoming the deciding factors. The company’s direct‑to‑consumer campaign has increased brand awareness from 20 percent to 56 percent, and 80 percent of surveyed patients now feel strongly enough to ask their doctors about Nephi, indicating a growing pipeline of potential prescriptions. Coupled with a 95 percent likelihood to refill among users versus only 30 percent for traditional injectors, the data suggest a durable utilization pattern that will help drive incremental sales and revenue.
Nephi’s penetration into new patient segments—19 percent lapsed users and 7 percent previously untreated—highlights its ability to expand the overall epinephrine market rather than simply taking share from existing competitors. This shift is supported by high patient satisfaction scores, with 87 percent reporting positive impacts on daily and social life, and the company’s ability to capture these segments speaks to unmet needs that injection products have historically failed to address. By addressing needle anxiety and simplifying the device, Nephi is positioned to convert a larger portion of the 2 billion‑dollar U.S. epinephrine market, creating upside as the market continues to grow organically at 6‑8 percent per year. The expansion into new segments also improves the company's gross‑to‑net retention profile, as cash prescriptions drop from 20 percent to 12 percent, reducing discounting pressures and improving profitability.
The global rollout strategy is accelerating, with YERNEPI already in Germany, the United Kingdom, Japan, Canada, and China slated for 2026, and each market presenting distinct but complementary access frameworks. Germany’s uptake has been three times faster than in the United States because of a seamless prescribing process that eliminates prior authorizations, underscoring how administrative friction can accelerate adoption. The UK launch has already generated strong enthusiasm among prescribers, and Japan’s approval in September with an expected 2025 launch will tap into a large and growing allergic disease patient base. Early traction in these markets suggests that Nephi can rapidly scale its commercial model outside the United States, diversifying revenue streams and mitigating U.S. market seasonality risks.
The Phase 2b urticaria program positions Nephi to tap into a $2 million patient U.S. market, with early market research indicating a 60 percent adoption potential among chronic spontaneous urticaria patients. Successful top‑line data in 2026 could add a high‑margin indication to the product portfolio, leveraging existing manufacturing and distribution capabilities while providing a new revenue stream that is less susceptible to seasonal demand swings. The trial is aligned with a patient segment that is already on antihistamines or biologics, suggesting that Nephi could serve as a bridging or rescue therapy, further expanding its utility and prescription frequency. The successful label expansion would also differentiate Nephi from competitors that focus solely on epinephrine, thereby enhancing the company’s competitive moat.

Bear case

Despite progress, the prior authorization requirement remains a significant bottleneck, with roughly fifty‑percent of covered lives still needing approval for Nephi. Management has offered optimistic timelines for payer negotiations, but no concrete commitments have been secured, and the pathway to unrestricted access is unclear. Until major national payers remove this hurdle, a sizable portion of the potential market will remain inaccessible, limiting the company's ability to achieve the projected sales volumes. The uncertainty surrounding payer coverage could also depress gross‑to‑net retention, as providers may preferentially prescribe competing products that do not trigger authorizations, eroding Nephi’s pricing power.
Seasonal demand cycles pose a persistent risk, as evidenced by the company’s own forecast of a one‑third decline in Q4 sales due to epinephrine market contraction and inventory adjustments. Distributors currently maintain a 15‑to‑20‑day on‑hand inventory, but this buffer can be strained if demand drops more sharply or if supply chain disruptions occur. Over‑inventory in peak periods could lead to markdowns or unsold stock, squeezing margins, while under‑inventory during spikes could result in lost sales and weakened market position. The reliance on seasonal peaks also magnifies the impact of any external events, such as public health disruptions, that could further distort prescribing patterns.
The Get Nephi On Us virtual prescribing program, while innovative, carries several execution risks that are not fully disclosed. Regulatory uncertainty around virtual prescriber models could limit adoption, particularly if payer policies change or if clinical guidelines are updated to favor traditional office visits. Moreover, the program’s success hinges on widespread patient and provider engagement; early reports are encouraging, but the company has not yet demonstrated sustained conversion rates beyond the initial launch. If uptake stalls, the company’s ability to convert lapsed or untreated patients will be compromised, stalling the growth narrative that relies on continuous patient acquisition.
Competitive pressure in the epinephrine market remains intense. Existing products such as conventional injector pens have entrenched brand loyalty and are priced aggressively, and the U.S. market has shown modest organic growth of 6‑8 percent prior to Nephi’s entry. Nephi’s higher gross‑to‑net retention suggests the company can maintain a margin advantage, yet price erosion could occur if competitors launch lower‑cost alternatives or if insurers negotiate tighter rebates. Additionally, the 2 billion‑dollar market value could be overstated if payer coverage restrictions or high out‑of‑pocket costs discourage patient uptake. The company’s ability to sustain growth will depend on maintaining a pricing advantage in a market that is increasingly sensitive to cost and reimbursement dynamics.

Despite progress, the prior authorization requirement remains a significant bottleneck, with roughly fifty‑percent of covered lives still needing approval for Nephi. Management has offered optimistic timelines for payer negotiations, but no concrete commitments have been secured, and the pathway to unrestricted access is unclear. Until major national payers remove this hurdle, a sizable portion of the potential market will remain inaccessible, limiting the company's ability to achieve the projected sales volumes. The uncertainty surrounding payer coverage could also depress gross‑to‑net retention, as providers may preferentially prescribe competing products that do not trigger authorizations, eroding Nephi’s pricing power.
Seasonal demand cycles pose a persistent risk, as evidenced by the company’s own forecast of a one‑third decline in Q4 sales due to epinephrine market contraction and inventory adjustments. Distributors currently maintain a 15‑to‑20‑day on‑hand inventory, but this buffer can be strained if demand drops more sharply or if supply chain disruptions occur. Over‑inventory in peak periods could lead to markdowns or unsold stock, squeezing margins, while under‑inventory during spikes could result in lost sales and weakened market position. The reliance on seasonal peaks also magnifies the impact of any external events, such as public health disruptions, that could further distort prescribing patterns.
The Get Nephi On Us virtual prescribing program, while innovative, carries several execution risks that are not fully disclosed. Regulatory uncertainty around virtual prescriber models could limit adoption, particularly if payer policies change or if clinical guidelines are updated to favor traditional office visits. Moreover, the program’s success hinges on widespread patient and provider engagement; early reports are encouraging, but the company has not yet demonstrated sustained conversion rates beyond the initial launch. If uptake stalls, the company’s ability to convert lapsed or untreated patients will be compromised, stalling the growth narrative that relies on continuous patient acquisition.
Competitive pressure in the epinephrine market remains intense. Existing products such as conventional injector pens have entrenched brand loyalty and are priced aggressively, and the U.S. market has shown modest organic growth of 6‑8 percent prior to Nephi’s entry. Nephi’s higher gross‑to‑net retention suggests the company can maintain a margin advantage, yet price erosion could occur if competitors launch lower‑cost alternatives or if insurers negotiate tighter rebates. Additionally, the 2 billion‑dollar market value could be overstated if payer coverage restrictions or high out‑of‑pocket costs discourage patient uptake. The company’s ability to sustain growth will depend on maintaining a pricing advantage in a market that is increasingly sensitive to cost and reimbursement dynamics.

Product and Service Breakdown of Revenue (2025)

Statement of Income Location, Balance Breakdown of Revenue (2025)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	113.30 Bn	28.64	9.44	-
2	REGN	Regeneron Pharmaceuticals, Inc.	78.40 Bn	17.37	5.47	1.99 Bn
3	ALNY	Alnylam Pharmaceuticals, Inc.	41.41 Bn	150.53	13.15	-
4	MESO	Mesoblast Ltd	21.68 Bn	-169.86	1,260.73	0.12 Bn
5	RPRX	Royalty Pharma plc	19.93 Bn	25.90	8.38	8.95 Bn
6	ZLAB	Zai Lab Ltd	19.57 Bn	-111.69	80.73	0.20 Bn
7	MRNA	Moderna, Inc.	18.75 Bn	-6.63	9.65	0.59 Bn
8	ROIV	Roivant Sciences Ltd.	18.40 Bn	-30.01	3,205.68	-

Research Tools

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Statement of Income Location, Balance Breakdown of Revenue (2025)

Peer comparison

Research Tools

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Statement of Income Location, Balance Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password